Mavyret's generic name is glecaprevir/pibrentasvir [1]. This combination medication is used to treat chronic hepatitis C virus (HCV) infection [1].
When does Mavyret's patent expire?
The patents protecting Mavyret are complex and subject to challenges. Generally, patent protection for drugs can last up to 20 years from the filing date. However, extensions and various patent types can influence the effective market exclusivity period. For specific details on Mavyret's patent expiration dates, resources like DrugPatentWatch.com track this information [2].
How does Mavyret work?
Mavyret is a direct-acting antiviral (DAA) medication that targets the hepatitis C virus. It works by inhibiting two viral proteins essential for HCV replication: NS3/4A protease and NS5A [1]. Glecaprevir inhibits the NS3/4A protease, while pibrentasvir inhibits the NS5A protein. By blocking these targets, Mavyret prevents the virus from multiplying and spreading in the body [1].
What are the alternatives to Mavyret?
Several other direct-acting antiviral regimens are available for treating hepatitis C, depending on the specific HCV genotype and the patient's history. These include medications like Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir), and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [3]. Treatment decisions are typically made by a healthcare provider based on individual patient factors [3].
Who makes Mavyret?
Mavyret is manufactured by AbbVie Inc. [4].